Century Therapeutics, Inc. (IPSC)Healthcare | Biotechnology | Philadelphia, United States | NasdaqCM
2.20 USD
-0.05
(-2.222%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 2.20 |
Hot Take ↕ | July 11, 2026, 6:27 a.m. EDT
Century Therapeutics presents a catastrophic long-term outlook despite a recent price bounce. The company has suffered four consecutive years of double-digit percentage declines, erasing nearly 98% of its value since 2021. Fundamentals are broken: the stock trades at a negative P/E, generates massive free cash flow losses, and has returned negative equity to shareholders. While the recent price action shows some resilience against the 200-day average, the underlying business trajectory is a structural implosion. The options market confirms this fear, with traders buying deep puts for years ahead while ignoring upside potential. The recent news of clinical progress offers hope, but the balance sheet and historical performance suggest the market views these developments as insufficient to reverse the multi-year decline. For investors, this is a value trap where the low price reflects a deteriorating asset, not a bargain. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.044646 |
| AutoETS | 0.045641 |
| AutoARIMA | 0.048245 |
| MSTL | 0.050809 |
| MSTL_74 | 0.157665 |
| MSTL_97 | 0.159445 |
| MSTL_74_97 | 0.287740 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 4.02 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.291 |
| Excess Kurtosis | -0.80 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 18.14 |
| Market Cap | 396,780,608 |
| Forward P/E | -4.81 |
| Beta | 1.56 |
| Website | https://www.centurytx.com |
As of July 11, 2026, 6:27 a.m. EDT: Speculators are heavily positioned for downside protection with massive open interest in deep out-of-the-money puts expiring in March 2027, while call activity is sparse and concentrated near the money. This asymmetry suggests a market consensus expecting significant further declines rather than a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.75 |
| Address1 | 25 North 38th Street |
| Address2 | 11th Floor |
| All Time High | 32.899 |
| All Time Low | 0.342 |
| Ask | 2.67 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 3,271,900 |
| Average Daily Volume3 Month | 1,296,129 |
| Average Volume | 1,296,129 |
| Average Volume10Days | 3,271,900 |
| Beta | 1.56 |
| Bid | 1.59 |
| Bid Size | 2 |
| Book Value | 1.47 |
| City | Philadelphia |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.2 |
| Current Ratio | 10.249 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 2.24 |
| Day Low | 2.08 |
| Debt To Equity | 18.14 |
| Display Name | Century Therapeutics |
| Earnings Timestamp | 1,778,675,400 |
| Earnings Timestamp End | 1,786,624,200 |
| Earnings Timestamp Start | 1,786,624,200 |
| Ebitda | -101,596,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -3.051 |
| Enterprise Value | 310,002,592 |
| Eps Current Year | -0.46 |
| Eps Forward | -0.4575 |
| Eps Trailing Twelve Months | -1.14 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.2856 |
| Fifty Day Average Change | -0.0855999 |
| Fifty Day Average Change Percent | -0.03745183 |
| Fifty Two Week Change Percent | 275.0 |
| Fifty Two Week High | 3.04 |
| Fifty Two Week High Change | -0.8399999 |
| Fifty Two Week High Change Percent | -0.27631578 |
| Fifty Two Week Low | 0.435 |
| Fifty Two Week Low Change | 1.7650001 |
| Fifty Two Week Low Change Percent | 4.0574713 |
| Fifty Two Week Range | 0.435 - 3.04 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,624,023,000,000 |
| Float Shares | 79,953,090 |
| Forward Eps | -0.4575 |
| Forward P E | -4.808743 |
| Free Cashflow | -53,628,000 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 78 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -86,192,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.08201 |
| Held Percent Institutions | 0.77924 |
| Implied Shares Outstanding | 180,354,809 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-06-18 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania. |
| Long Name | Century Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 396,780,608 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_626518430 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -107,785,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 406,700,094 |
| Number Of Analyst Opinions | 4 |
| Open | 2.24 |
| Operating Cashflow | -94,515,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 267 817 5790 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 2.2 |
| Post Market Time | 1,783,977,844 |
| Previous Close | 2.25 |
| Price Eps Current Year | -4.7826085 |
| Price Hint | 4 |
| Price To Book | 1.4965986 |
| Price To Sales Trailing12 Months | Infinity |
| Profit Margins | 0.0 |
| Quick Ratio | 10.038 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.05 |
| Regular Market Change Percent | -2.22222 |
| Regular Market Day High | 2.24 |
| Regular Market Day Low | 2.08 |
| Regular Market Day Range | 2.08 - 2.24 |
| Regular Market Open | 2.24 |
| Regular Market Previous Close | 2.25 |
| Regular Market Price | 2.2 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 1,711,653 |
| Return On Assets | -0.22284001 |
| Return On Equity | -0.42672002 |
| Revenue Per Share | 0.0 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 180,354,809 |
| Shares Percent Shares Out | 0.1301 |
| Shares Short | 23,456,373 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 12,466,530 |
| Short Name | Century Therapeutics, Inc. |
| Short Percent Of Float | 0.131 |
| Short Ratio | 12.0 |
| Source Interval | 15 |
| State | PA |
| Symbol | IPSC |
| Target High Price | 8.0 |
| Target Low Price | 2.0 |
| Target Mean Price | 4.75 |
| Target Median Price | 4.5 |
| Total Cash | 134,803,008 |
| Total Cash Per Share | 0.747 |
| Total Debt | 48,025,000 |
| Total Revenue | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.14 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.641995 |
| Two Hundred Day Average Change | 0.5580051 |
| Two Hundred Day Average Change Percent | 0.33983362 |
| Type Disp | Equity |
| Volume | 1,711,653 |
| Website | https://www.centurytx.com |
| Zip | 19,104 |